Stryker Corporation
SYK Healthcare Medical Devices
Stryker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $25.1 billion, up 11.2% from fiscal 2024. In the quarter to June 2026, revenue grew 9.42%, EPS grew 43.1%, free cash flow grew 14.1% and total debt fell 9.88%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five, operating cash flow growth for three.
Follow SYK
Stryker Corporation (SYK) EPS (diluted)
Stryker Corporation's EPS (diluted) for fiscal 2025 was $8.40, up 8.25% from $7.76 in fiscal 2024. Over the twelve months to 30 June 2026 it was $9.65. Over the past ten years it has ranged from $2.68 (fiscal 2017) to $9.34 (fiscal 2018); the current reading is higher than 91% of that period. Stryker Corporation ranks 4th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $8.40 | 8.25% |
| FY2024 | $7.76 | (5.94%) |
| FY2023 | $8.25 | 33.71% |
| FY2022 | $6.17 | 18.43% |
| FY2021 | $5.21 | 24.05% |
| FY2020 | $4.20 | (23.36%) |
| FY2019 | $5.48 | (41.33%) |
| FY2018 | $9.34 | 248.51% |
| FY2017 | $2.68 | (38.39%) |
| FY2016 | $4.35 | 15.08% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $3.30 | 70.98% |
| Mar 2026 | $1.93 | (12.27%) |
| Dec 2025 | $2.20 | (0.90%) |
| Sep 2025 | $2.22 | (3.06%) |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| SYK Stryker Corporation | $9.65 |
| STE STERIS plc compare | $8.18 |
| GEHC GE HealthCare Technologies Inc. compare | $4.36 |
| MDT Medtronic PLC compare | $4.06 |
| ABT Abbott Laboratories compare | $3.09 |
| DXCM DexCom, Inc. compare | $2.53 |
| BSX Boston Scientific Corporation compare | $2.47 |
| EW Edwards Lifesciences Corporation compare | $1.74 |
| PHG Koninklijke Philips N.V. compare | $1.36 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on SYK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement